Navigation Links
Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
Date:3/14/2011

BEDMINSTER, N.J., March 14, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms.  Existing investor, Sofinnova Partners, also participated in the financing. The capital raised will be used to fund the Phase 3 clinical development of Omthera's novel Omega-3 fatty acid compound, Epanova™, and for general corporate purposes.  With this latest round, Omthera has raised approximately $40.4 million in venture capital since commencement of operations in 2009.

In a separate press release issued today, Omthera announced that the Company has initiated its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova, for the treatment of patients with very high triglycerides (greater than or equal to 500 mg/dL).  In January 2011, the Company announced data from its ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation) trial, designed to evaluate the bioavailability of Epanova in comparison to Lovaza®, the leading prescription Omega-3.  Data from the trial showed that the bioavailability of Epanova was dramatically superior to Lovaza.

"Omthera continues to generate very positive data indicating that Epanova has the potential to become the best-in-class therapy in the nearly $2 billion worldwide Rx Omega-3 market and an important treatment for the millions of patients suffering from high triglycerides," stated Jerry Wisler, President, Chief Executive Officer and co-founder of Omthera. "As such, we are delighted to gain the support of a venture capital firm of the stature of NEA to lead this substantial new funding."  

David M. Mott, f
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... -- July 4 th is this weekend, a time we ... people behind it. To help honor our current nation,s heroes, ... Medical Card, a leading provider of free pharmacy ... independence for our disabled military veterans, police, firemen, and EMS ... prescriptions. "Due to USA ...
(Date:6/30/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/pggcjf/global_endoscopy ) ... Endoscopy Devices Market 2015-2019" report to their ... to grow at a CAGR of 5.53% over ... market can be segmented into three based on ... market can be further segments in terms of ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3
... that it will report its 2011 first quarter earnings on Friday, ... host an analyst and investor call at 10:00 AM EDT live ... participate in the conference call within the U.S. and Canada, dial ... dial (708) 290-1340. The conference ID is 74735682. ...
... 14, 2011 Cardinal Health today opened its first ... its nationwide capability to manufacture molecular imaging biomarkers that ... cancer, neurological disorders and heart disease. Cyclotrons ... Tomography (PET) molecular imaging agents, one of the fastest-growing ...
Cached Medicine Technology:Cardinal Health Extends Radiopharmaceutical Manufacturing Network, Opening its First Cyclotron in Georgia 2Cardinal Health Extends Radiopharmaceutical Manufacturing Network, Opening its First Cyclotron in Georgia 3
(Date:6/30/2015)... ... June 30, 2015 , ... Board certified otolaryngologist Dr. ... Center . , Dr. Antunes is a fellowship trained facial ... procedures. In addition to performing cosmetic and reconstructive surgery on the face, he ...
(Date:6/30/2015)... ... 2015 , ... The United Nations Foundation’s Universal Access Project, in partnership with ... Care Youth contest today. Why We Care Youth serves as a platform for young ... has personally meant to them, and why U.S. policymakers should care about expanding access ...
(Date:6/30/2015)... ... June 30, 2015 , ... NJ Top Dentist, Dr. ... 13th, she hosted a CPR Course for members of the Bergen County Dental Society. ... updated on the latest CPR recommendations for Healthcare Providers. Life Support from Hackensack ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... testosterone claims alleging heart attack and stroke incidents are linked to testosterone replacement ... The Case Management Conference is scheduled for July 9, 2015, according to court ...
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... ... specializing in affordable addiction care in Florida on June 12th. Holly Vasquez-Cortella ... The Fix - a website dedicated to reporting on trending addiction news and ...
Breaking Medicine News(10 mins):Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 2Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 3Health News:UN Foundation, Planned Parenthood Federation of America & Sierra Club Launch Why We Care Youth to Amplify Young Voices on Critical Importance of International Reproductive Health and Contraception 4Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 2Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3
... may be an independent cause of excessive daytime ... occurrences. Researchers from Sweden performed polysomnography testing on ... years. The apnea-hypopnea index (AHI) was calculated, and ... or very often were considered habitual snorers. Habitual ...
... Nov. 11 What would make 100,000 people,stand in ... will be answered November 28, 29 at St. Peter ... in Burlingame on,November 30 when Issam Nemeh, M.D. arrives ... A cardiothoracic anesthesiologist, Dr.,Nemeh has become known as "The ...
... DIEGO, Nov. 11 Orthodontists have been,straightening teeth ... action has a reaction," in which tooth displacement ... the other as well. Use of dental implants ... expediting,treatment times and expanding possibilities for previously untreatable,cases, ...
... Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, ... ScD, at LSU Health Sciences Center New Orleans School ... most comprehensive assessment of the burden of human papillomavirus ... report, "Assessing the Burden of Human Papillomavirus (HPV)-Associated ...
... Philanthropy Day Celebration Honors City,s Exemplary Orgs., ... ... Red Cross of Greater,Los Angeles will be honored as the Outstanding Volunteer ... at the Beverly Hilton Hotel., This award is given annually to ...
... from dose-ranging study of new,oral anti-coagulant in patients with ... to begin in December., NEW ORLEANS, Nov. 11 ... anti-clotting agent -- rivaroxaban -- designed to,identify doses that ... efficacy,and safety trials. The results of ATLAS ACS-TIMI 46 ...
Cached Medicine News:Health News:Journal CHEST: Nov. highlights 2Health News:A New Meaning of Thanksgiving: Miracles for Many, Prayers for All as Healing Services Come to San Francisco 2Health News:Dental Implants Effective for Orthodontic Treatment 2Health News:LSUHSC public health contributes to estimate of HPV-related cancers 2Health News:LSUHSC public health contributes to estimate of HPV-related cancers 3Health News:LSUHSC public health contributes to estimate of HPV-related cancers 4Health News:American Red Cross of Greater Los Angeles Named Outstanding Volunteer Organization 2Health News:Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data 2Health News:Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data 3Health News:Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data 4
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: